Vol. 11 No. 1 (2019): Archives of Public Health
Clinical Science

Quality of life assessment in patients treated with medicaments for benign prostatic hyperplasia

Maja Sofronievska-Glavinov
University Clinic for Surgical Diseases „St. Naum Ohridski“, Skopje, Republic of North Macedonia
Svetlana Jovevska
Faculty of Medicine, University Goce Delcev, Stip, Republic of North Macedonia
Mihail Kocubovski
Institute of public health of Republic of North Macedonia, Skopje, Republic of North Macedonia

Published 2019-04-06

Keywords

  • benign prostatic hyperplasia,
  • symptoms,
  • quality of life

How to Cite

1.
Софрониевска-Главинов М, Јовевска С, Кочубовски М. Quality of life assessment in patients treated with medicaments for benign prostatic hyperplasia. Arch Pub Health [Internet]. 2019 Apr. 6 [cited 2022 Oct. 2];11(1):89-94. Available from: https://www.id-press.eu/aph/article/view/2860

Abstract

The purpose of this study was to determine the impact of symptoms and the effects of drug treatment on the quality of life in patients with benign prostatic hyperplasia. We evaluated two groups of patients with the International Prostate Scoring System questionnaire, the Beck depression inventory and an issue/question on quality of life. The first (control) group consisted of patients with benign prostatic hyperplasia who were on alpha-blocker therapy, while the second group of patients (examined) were on combination therapy with alpha blocker and 5-alpha reductase inhibitor. In analyzing the results, we came to the conclusion that patients in the control group had a better quality of life and psychosocial status due to the weaker symptoms of the disease. Patients in the second group had a poorer quality of life due to development of side effects of 5-alpha reductase inhibitors therapy: erectile dysfunction and depression. Modalities in the therapeutic approach enable improvement of the symptoms in the second group and improvement of the quality of life in patients with dual therapy for BPH.

Downloads

Download data is not yet available.

References

  1. . Trueman P, Hood SC, Nayak USL, Mrazeik MF. Prevalenceof lower urinary tract symptoms and self-reported diagnosed‘benign prostatic hyperplasia’, and their effect onquality of life in a community-based survey of men in theUK. BJU Int 1999;83:410–5.
  2. . Roehrborn CG. Benign Prostatic Hyperplasia: An Overview. Rev Urol 2005; 7:3–14.
  3. . BoschJL, HopWC , KirkelsWJ, Schröder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community.Urology 1995; 46 : 34-40.
  4. .Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474–479.
  5. . Sarma AV, Jacobson DJ, McGree ME, Roberts RO, LieberMM, Jacobsen SJ. A population based study of incidenceand treatment of benign prostatic hyperplasia amongresidents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005;173:2048–53.
  6. . Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008;72:318–321
  7. Browne CT, Emberton M. Self-management for men with lower urinary tract symptoms. Curr Urol Rep 2009;10:261-67.
  8. .Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148(5):1549–57
  9. .Chapple C, Abrams P, editors. Male lower urinary tract symptoms (LUTS). An international consultation. Montreal, Canada: International Consultation on Urological Diseases (ICUD); Societe Internationale d’Urologie;2013.
  10. . Brubaker L, Khullar V, Piault E, et al. Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J 2011; 22(8):937–46.
  11. . Liu L, Zhao S, Li F, Li E, Kang R, Luo L, et al. Effect of 5 alphareductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med 2016;13(9):1297–310.
  12. . Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5 alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J SexMed 2011;8(3):872–84.
  13. . Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5 alpha-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J ClinPract 2012;66(11):1052–5.